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Multiple lines of evidence are indicating that cancer development and malignant
progression are not exclusively epithelial cancer cell-autonomous processes but
may also depend on crosstalk with the surrounding tumor microenvironment (TME).
Cancer-associated fibroblasts (CAFs) are abundantly represented in the TME and are
continuously interacting with cancer cells. CAFs are regulating key mechanisms during
progression to metastasis and response to treatment by enhancing cancer cells survival
and aggressiveness. The latest advances in CAFs biology are pointing to CAFs-secreted
factors as druggable targets and companion tools for cancer diagnosis and prognosis.
Especially, extensive research conducted in the recent years has underscored the
potential of several cytokines as actionable biomarkers that are currently evaluated in the
clinical setting. In this review, we explore the current understanding of CAFs secretome
determinants and functions to discuss their clinical implication in oncology.
Keywords: cancer-associated fibroblast (CAF), secretome, secreted factors, growth factors, cancer, tumor
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INTRODUCTION
Cancer-associated fibroblasts (CAFs) are contributing to the production of a wide variety of
secreted factors impacting tumor progression by directly regulating malignant cancer cells
aggressiveness or by indirectly reprogramming tumor immunity and angiogenesis (Sahai et al.,
2020). Hence, molecular and functional inter- and intra-tumoral heterogeneity of CAFs has been
a recent focus in oncology research. It is widely accepted that the functional phenotype of CAFs
is in part determined by the cell of origin, including but not restricted to local resident fibroblasts
(D’Arcangelo et al., 2020; Sahai et al., 2020). An alternative hypothesis advocating for CAF being
a cell state depending on autocrine and paracrine signaling rather than a cell type has also been
proposed (Kalluri, 2016). Whether CAFs functional heterogeneity is maintained among different
solid tumor types or is a constant evolutionary state is still a debated question. However, recent
studies have been investigating the determinants of CAFs secretome and their therapeutic interest
across different tumor types. Molecular biomarkers predicting the risk of relapse and the potential
benefit from treatments are currently needed for clinical decision-making. In an attempt to reach
a more comprehensive evaluation of tumors, many CAFs-secreted factors have been included in
gene expression signatures that are considered suitable prognostic tools for clinical diagnosis and
prognostication (Berdiel-Acer et al., 2014; Karlan et al., 2014; Yue et al., 2019). As a matter of fact,
recent advances in the understanding of CAFs secretome determinants and functions have brought
to light the multiple benefits of using CAFs-secreted factors as actionable biomarkers for cancer
diagnosis, treatment, and prognosis.
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DETERMINANTS OF CAFS SECRETOME
Crosstalk With Tumor Cells and TME
Components
Autocrine- and Paracrine-Secreted Factors
Multiple autocrine loops impacting CAFs secretome have been
discovered in the recent years (Figure 1). Among them, members
of the transforming growth factor beta (TGF-beta) superfamily
are known to be the main inducers of CAFs activation. Of
note, CAFs secrete large amounts of TGF-beta isoforms 1,
2, and 3 (reviewed in Kalluri, 2016). In turn, secreted TGF-
beta maintains a self-sustained active state -typically regarded
as myofibroblasts- characterized by alpha smooth muscle actin
(alpha-SMA) expression (Orimo et al., 2005; Kojima et al.,
2010). Other members of the TGF-beta superfamily, such as
Nodal, induce pro-tumorigenic phenotypes in fibroblasts from
melanoma and colorectal cancer (CRC) (Li et al., 2019). Likewise,
activin A has showed the ability to induce a secretory phenotype
in CAFs via the SMAD-2-mediated transcriptional regulation
of genes encoding extracellular matrix (ECM) components,
ECM regulators, and soluble factors (Cangkrama et al., 2020).
Alternatively, CAFs secretome may be maintained during tumor
progression through enhanced stromal cell-derived factor (SDF)-
1 autocrine signaling loops and increased co-expression of
receptors, such as TGF-beta-RI and CXC receptor (CXCR)-
4 (Kojima et al., 2010). In this sense, Scherz-Shouval et al.
reported an increased production of TGF-beta-2 and SDF-1
factors by CAFs upon heat shock factor (HSF)-1 cytoplasmic
translocation to the nucleus (Scherz-Shouval et al., 2014). HSF-
1 is a transcription factor that mediates the cellular response to
Abbreviations: AKT, protein kinase B; ATRA, all-trans retinoic acid; CCL, C–
C motif chemokine; COX2, cyclooxygenase 2; CXC, C–X–C motif chemokine;
CXCL, CXC ligand; CXCR, CXC receptor; DKK-1, Dickkopf-related protein
1; FGF, fibroblast growth factor; GDF-15, growth differentiation factor 15;
GM-CSF, granulocyte-macrophage colony-stimulating factor; HER3, epidermal
growth factor receptor 3; HGF, hepatocyte growth factor; HIF, hypoxia-inducible
factor; HspA1A, heat shock 70 kDa protein 1A; ICAM-1, intercellular adhesion
molecule 1; IFN, interferon; IGF, insulin-like growth factor; IGF1R, IGF 1
receptor; IGFBP, insulin-like growth factor-binding protein; JAK, Janus kinase;
JNK, Jun N-terminal kinase; KLK, kallikrein; LIF, leukemia inhibitory factor; M-
CSF, macrophage colony-stimulating factor; MAPK, mitogen-activated protein
kinase; MCP-1, monocyte chemoattractant protein 1; MIF, macrophage migration
inhibitory factor; MMP, matrix metallopeptidase; mTOR, mammalian target of
rapamycin;MYH-11,myosin 11; NF-κB, nuclear factor-kappa B; NRG, neuregulin;
OXPHOS, oxidative phosphorylation system; P38 MAPK, p38 mitogen-activated
protein kinase; PDGF, platelet-derived growth factor; PDGFRB, platelet-derived
growth factor receptor beta; PDPN, podoplanin; PGE2, prostaglandin E2; PI3K,
phosphoinositide 3-kinase; POSTN, periostin; PAR, protease-activated receptor;
RAGE, receptor for advanced glycation end products; miRNA,microRNA;mRNA,
messenger RNA; lncRNA, long non-coding RNA; S100A11, S100 calcium-binding
protein A11; SATB-1, special AT-rich sequence-binding protein-1; SDF, stromal
cell-derived factor; SFRP4, secreted frizzled-related protein 4;Shp, Src homology 2-
containing protein tyrosine phosphatase; SMAD, acronym for a signal transducer
family; SOCS, suppressor of cytokine signaling 1; STAT, signal transducer and
activator of transcription; TAZ, transcriptional coactivator with PDZ-binding
motif, also known as Wwtr1; TET, ten-eleven translocation enzyme; THBS,
thrombospondin; TIMP, tissue inhibitors of MMP;TNC, tenascin C; TNF, tumor
necrosis factor; TPL2, tumor progression locus 2; VCAM, vascular cell adhesion
protein; VEGF, vascular endothelial growth factor; VEGFA, VEGF type A; YAP,
yes-associated protein.
different types of stress, such as hypoxia or proteotoxic stress
(Dayalan Naidu and Dinkova-Kostova, 2017).
Complex paracrine signaling through cancer cell-secreted
factors also regulates CAFs secretome during tumor progression
(Figure 1) and may depend on genetic alterations occurring
in cancer cells. Indeed, KRAS mutant but not KRAS wild-
type pancreatic ductal adenocarcinoma (PDAC) cancer cells
induce CAFs activation through CXCR-2, leading to a nuclear
factor-kappa B (NF-κB)-mediated secretion of pro-tumoral
cytokines interleukin (IL)-4, IL-10, and IL-13 (Awaji et al.,
2020). Several additional studies have reported a pro-tumorigenic
crosstalk between cancer cells and CAFs. For instance, kallikrein
(KLK)-4 produced by malignant and premalignant prostate
lesions can act on normal fibroblasts through the activation of
protease-activated receptor (PAR)-1, which leads to a CAF pro-
angiogenic secretory phenotype characterized by the increased
expression of Dickkopf-related protein 1 (DKK-1), growth
differentiation factor 15 (GDF-15), hepatocyte growth factor
(HGF), IL-8, and vascular endothelial growth factor (VEGF)
and the decreased expression of insulin-like growth factor-
binding protein (IGFBP)-3, monocyte chemoattractant protein 1
(MCP-1), and platelet-derived growth factor (PDGF)-AA (Kryza
et al., 2017). In PDAC, S100 calcium-binding protein A11
(S100A11) secreted by cancer cells activates the surrounding
fibroblasts through the S100A11–receptor for advanced glycation
end products (RAGE)–tumor progression locus 2 (TPL2)–
cyclooxygenase 2 (COX2) pathway to promote metastatic
progression (Mitsui et al., 2019).
CAFs activation may also occur through paracrine signaling
with non-cancer cells. For example, cytokines produced by
immune cells during the inflammatory process may instruct
CAFs function. Among them, IL-1β produced by immune cells in
early hyperplastic lesions activates normal fibroblasts to become
CAFs via the NF-κB pathway (Erez et al., 2010). Alternatively,
granulin secretion by macrophages activates resident fibroblasts
into tumor-promoting myofibroblasts sustaining metastatic
growth in PDAC (Nielsen et al., 2016).
In addition to local intra-tumoral autocrine and paracrine
signaling, systemic signaling involving steroid hormones, such
as estrogens and androgens, is also able to modulate CAFs
secretome, through binding to their receptors expressed in
CAFs (Clocchiatti et al., 2018; Rothenberger et al., 2018).
For instance, estrogens (E2) regulate the expression of several
microRNAs (miRNAs) in breast cancer (BC)-derived CAFs
(Vivacqua et al., 2019). In gastric cancer, estrogens stimulate
CAFs secretion of IL-6, thereby promoting signal transducer and
activator of transcription (STAT)-3 pathway-dependent cancer
cells proliferation and invasion (Zhang Y. et al., 2020). Similarly,
in prostate cancer (PCa), the activation of CAFs–androgen
receptor (AR) with dihydrotestosterone modulates the secretion
of pro-tumorigenic factors impacting cancer cell growth (Tanner
et al., 2011). Conversely, AR blockade in CAFs decreases
the expression of pro-tumorigenic factors, such as insulin-like
growth factor (IGF)-1, fibroblast growth factor (FGF)-7, FGF-10,
SDF-1, HGF, and TGF-beta 2 (Yu et al., 2013).
As illustrated by the opposite gene expression programs
regulated upon FGF and TGF-beta pathway activation
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FIGURE 1 | Determinants of CAFs secretome during cancer progression. Secreted factors as well as extracellular vesicle (EV)-dependent autocrine and paracrine
crosstalk modulate the secretory profile of CAFs. Direct physical interaction between CAFs and epithelial cancer cells or between CAFs and components of the
extracellular matrix may additionally regulate CAFs secretome.
(Bordignon et al., 2019), CAFs secretome heterogeneity may be
the result of a delicate balance between autocrine and paracrine
signaling stimulated simultaneously and activating CAFs in
different ways. It is worth noting that autocrine and paracrine
triggering cues educating CAFs secretory functions may be
tumor-dependent or even cancer subtype-dependent. Thus,
the identification of multiple CAFs activation and secretion
programs could greatly improve current molecular classification
of cancer.
Extracellular Vesicles
Extracellular vesicles (EVs) are spherical membrane formations
comprising exosomes and microvesicles, which can carry
different molecules, such as proteins, DNAs, non-coding RNAs,
and miRNAs/mRNAs. While both are playing a key role in
distant intercellular communication, exosomes are derived from
the endosomal system, and microvesicles are produced by the
plasma membrane (reviewed in van Niel et al., 2018). EV-
based intercellular communication between cancer cells and the
tumor microenvironment (TME)–including CAFs (Figure 1)–
promotes cancer progression in multiple ways (reviewed in Han
et al., 2019); however, EVs’ ability to induce a secretory phenotype
in CAFs still remains an open field of research (Webber
et al., 2015). In some cases, tumor cell-derived EVs contain
typical mitogenic factors, such as TGF-beta, which in ovarian
cancer induces a pro-tumoral secretome leading to increased
proliferation, motility, and invasiveness of ovarian cancer cells
(Giusti et al., 2018). Furthermore, an increasing body of evidence
points to the importance of EV-derived miRNA. For instance, in
gastric cancer, EVs containing miR155, miR193b, and miR210
prime CAFs to secrete inflammatory chemokines, such as CXC
ligand (CXCL)-1 and CXCL-8, through the activation of the Janus
kinase (JAK)/STAT and NF-κB signaling pathways (Naito et al.,
2019). Similarly, NF-κB activation in CAFs by EV-derived miR-
1247-3p in metastatic hepatocellular carcinoma (HCC) leads to a
tumor-promoting secretion of IL-6 and IL-8 (Fang et al., 2018).
Alternatively, EV-derived miR-210 and miR-155-5p induce a
pro-angiogenic switch in CAFs through the activation of the
JAK-2/STAT-3 pathway in lung cancer and melanoma (Zhou
et al., 2018; Fan et al., 2020). Additional signaling pathways have
been associated with miRNA-driven secretory stimulation. For
instance, EVs containing miR-10b contribute to the enhanced
TGF-beta expression in CAFs through the phosphoinositide
3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of
rapamycin (mTOR) signaling pathway in CRC (Dai et al., 2018).
Finally, EVs containing coding mRNA have also been reported to
trigger a secretory phenotype in CAFs. In this sense, cancer cell-
derived EVs containing mRNA coding for CXCR-4 and IGF-1R
promote CAFs secretion of growth factors, such as VEGF in acute
myeloid leukemia (Huan et al., 2013).
Interestingly, EV-induced CAFs may in turn shed
additional EVs that will further support tumor growth by
conferring enhanced proliferative and survival capabilities to
cancer cells, thus establishing an EV-mediated bidirectional
intercommunication (Savardashtaki et al., 2019; Yang et al.,
2019). For instance, CAFs exposed to cancer cell-derived EVs
in Hodgkin lymphoma are primed to secrete EVs together with
pro-inflammatory cytokines and angiogenic factors (Dörsam
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et al., 2018). Similar to cancer cell-derived EVs, CAF-derived
EVs contain commonly miRNA, which has been described to
promote migration and resistance to treatment in several tumors
(Dourado et al., 2019; Hu et al., 2019; Qin et al., 2019; Sun et al.,
2019; Wang J.-W. et al., 2019). Besides miRNA, CAF-derived
EVs containing mitochondrial mRNA can educate cancer
cells to increase oxidative phosphorylation system (OXPHOS)
metabolism, which consequently induces escape from dormancy
(Sansone et al., 2017).
EV-mediated activation of CAFs can also occur indirectly
through stromal cell mediators present in the TME. Indeed,
a recent study showed that tumor-associated macrophages
incorporate and transfer cancer cell-derived EVs to CAFs, which
allows the formation of a pro-tumorigenic microenvironment
(Umakoshi et al., 2019).
Moreover, EVs content may be changing during tumor
progression, which could result in a temporal modulation
of CAFs secretory phenotypes. Supporting this notion, EVs
derived from primary or metastatic CRC promote different CAF
functional profiles, switching from a pro-angiogenic to a more
ECM remodeling phenotype (Rai et al., 2019). Therefore, EV-
mediated communication between tumor cells and CAFs may
depend on alterations in the composition of secreted EVs during
tumor progression. However, additional research is needed to
confirm this hypothesis.
Cell–Cell Contact and Mechanical Interactions
CAFs/cancer cells physical interactions can modulate CAFs
functions (Yamaguchi and Sakai, 2015), and the high complexity
of this interplay has been recently illustrated (Arwert et al.,
2020). For instance, CAFs may sense cancer cell genomic stress
through cytoplasmic transcytosis and respond by expressing
interferon (IFN)-β1, leading to an increased production of
chemokines, cytokines, and other inflammatory factors [CXCL-1
and 10, granulocyte-macrophage colony-stimulating factor
(GM-CSF), macrophage migration inhibitory factor (MIF),
IL-6, and IL-8, among others] (Arwert et al., 2020). Hetero-
cellular gap junction communications have also been described
between CAFs and cancer cells. This mechanism promoting
epithelial-to-mesenchymal transition (EMT), migration,
and invasiveness appears to be rather unidirectional—from
CAFs toward cancer cell (Luo et al., 2018); however, a better
understanding of the underlying molecular mechanisms
is still required.
Mechano-sensing between CAFs and the surrounding
ECM may equally modulate CAFs secretome. For example,
matrix stiffness and contractile forces have been shown to
determine CAFs behavior through different mechano-sensitive
pathways. Among them, non-canonical YAP pathway activation
is promoting CAFs ECM remodeling and angiogenic functions
(Calvo et al., 2013). Indeed, secretion of pro-angiogenic VEGF-A
by CAFs depends on factors involved in YAP pathway activation
(Calvo et al., 2015).
These findings suggest a significant role of physical
interactions in determining CAFs secretory phenotype.
Remarkably, spatial (invasive front or tumor core) as well
as temporal (early or late stage cancer) characteristics may
influence mechano-sensing and should be considered when
studying forces instructing CAFs secretory functions (Acerbi
et al., 2015; Bauer et al., 2020).
Spatial and Temporal Plasticity
Intra-tumor heterogeneity of CAFs functional subtypes and their
differential spatial pattern are already a widespread knowledge
(Lambrechts et al., 2018; Awaji and Singh, 2019; Neuzillet et al.,
2019). Thus, an effect of CAFs intra-tumoral location upon
their secretory functionmay be expected. Remarkably, fibroblasts
located next to the invasive front of BC show higher capacity
to induce cancer cells migration and EMT in comparison with
those located in the epicenter of the tumor (Gao et al., 2010).
In pancreatic cancer, two spatially separated subtypes were
identified (Figure 2). An inflammatory CAFs subtype (iCAFs),
distant from cancer cells, showed a secretory phenotype with
high interleukin and chemokine production [leukemia inhibitory
factor (LIF), IL-6, IL-11, IL-1, CXCL-1] in comparison with
periglandular myofibroblastic CAFs (myoCAFs), specialized in
stromal remodeling functions (Öhlund et al., 2017). However,
these two subtypes may be the borders of a functional spectrum
depending on IL-1-R1 expression, conditioned by the balance
between TGF-beta (pro-myoCAFs) and IL-1/JAK/STAT (pro-
iCAFs) signaling activation (Biffi et al., 2019). An additional
antigen-presenting CAFs (apCAFs) population activating CD4+
T cells was recently identified in PDAC (Figure 2), suggesting
CAFs subtype-specific immunomodulatory capacity (Elyada
et al., 2019). Along this line, Neuzillet and colleagues highlighted
the complexity of CAFs heterogeneity in PDAC, describing at
least four different functional and spatially distributed subtypes
depending on periostin (POSTN), myosin 11 (MYH-11), and
podoplanin (PDPN) expression (Neuzillet et al., 2019). Similarly,
in BC (Figure 2), a subset of myofibroblastic CAFs (CAF-
S1: CD-29Med FAPHi FSP-1Low−Hi αSMAHi PDGFRbMed−Hi
CAV-1Low) secreting differentially higher amount of CCL-11,
CXCL-12, CXCL-13, and CXCL-14 was predominantly detected
close to epithelial tumor cells (Costa et al., 2018). The other
myofibroblastic (αSMAHi) CAF-S4 subtype was preferentially
located within the tumor tissue, whereas CAF-S3 (FSP-1Med and
PDGFRbMed−Hi) was detected in the juxta tumoral healthy tissue.
CAF-S2 subtype (low or negative expression of stromal markers)
appeared to be equally distributed in both areas (Costa et al.,
2018).
For greater complexity, temporal evolution of CAFs during
tumor progression makes it difficult to assess the exclusive
effect of spatial distribution (Kalluri, 2016; D’Arcangelo et al.,
2020). Indeed, Nidogen-2, a protein secreted by “vascular CAFs”
in murine BC model, was firstly detected among perivascular
cells but relocated within the tumor stroma at later stages of
tumor progression (Bartoschek et al., 2018). In PDAC patients,
different phenotypes were detected by CAFs secretome analysis
of primary tumors and matched metastatic tissue (Öhlund
et al., 2017). In addition, the above-mentioned S1 and S4 CAFs
subsets have been recently found to be enriched in metastatic
BC lymph nodes in comparison with matched primary tumor
tissue (Costa et al., 2018; Pelon et al., 2020). In this setting,
CXCL-12 secretion was found to be responsible of CAF-S1
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FIGURE 2 | Several CAFs subtypes have been recently described in cancers of distinct origin. CAFs heterogeneity is associated with specific markers and discrete
functions. Remarkably, CAFs characteristics may be related to their spatial localization in the tumor.
tumor-promoting phenotype, whereas CAF-S4 seemed to be
specialized in NOTCH-dependent contractile and remodeling
functions (Pelon et al., 2020). Similarly, CAFs isolated from
prostate tumors at different stages revealed that CAFs secretome
evolves during PCa development. While localized PCa-
derived CAFs are characterized by FGF-7 secretion, CAFs
from metastatic PCa showed increased levels of matrix
metallopeptidase (MMP)-11 and heat shock 70 kDa protein 1A
(HspA1A) (Eiro et al., 2017).
As previously mentioned, increasing evidence suggests that
PCa-derived CAFs secretome is modulated by AR signaling (Yu
et al., 2013; Cioni et al., 2018). Interestingly, AR expression
by CAFs evolves during PCa progression (Olapade-Olaopa
et al., 1999; Gevaert et al., 2018). Indeed, metastatic PCa and
castration resistance PCa display significantly lower stromal
AR expression than localize tumor- and androgen-dependent
PCa (Li et al., 2008; Singh et al., 2014). These observations
suggest that a temporal regulation of CAFs secretome may occur
through the modulation of hormone receptors expression during
cancer progression.
Overall, a complex relationship between temporal and
spatial influence may instruct CAFs secretome. However,
it is still unknown whether tumor progression orchestrates
CAFs function and plasticity according to spatial factors
or, conversely, distinct CAFs spatial subtypes are modeling
tumor dynamics.
Anti-cancer Therapy as a Determinant of
CAFs Secretome
Chemotherapy
Several studies have addressed the modulatory effect of standard
chemotherapy (CT) on the TME. CT induces shrinkage of cancer
cells compartment resulting in an increased representation of
stromal cells in residual tumors (Goto et al., 2017). In this
context, factors secreted by CAFs after CT may significantly
enhance tumor regrowth from residual cancer cells (Hisamitsu
et al., 2019). Current evidence points to CT-induced DNA
damage being a key mechanism influencing the repertoire of
CAF-secreted factors after treatment (Figure 3). Indeed, CAFs
support tumor regrowth after DNA damage-mediated NF-κB
signaling activation through secretion of WNT-16B (Sun et al.,
2012). Alternatively, treatment of lung adenocarcinoma with
cisplatin enhances IL-11 secretion by CAFs, which in turn
promotes resistance of cancer cells to CT through the STAT-3
signaling pathway (Tao et al., 2016). Of note, CAF-induced IL-
11/STAT-3 cell–cell survival signaling has been reported in other
tumor types (Calon et al., 2012). Thus, CAF-dependent IL-11
resistance mechanism may be of potential relevance in cancers
of distinct origin. Similarly, a direct effect of gemcitabine and
5-FU regimen toward a tumor-supportive secretory phenotype
of CAFs has been described in PDAC. In that case, higher
expression of secreted factors [intercellular adhesion molecule
1 (ICAM-1), IL-6, GM-CSF, IL-8, CXCL-1] upon treatment has
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FIGURE 3 | Anti-cancer therapy impacts CAFs secretome. Stromal elements
develop their own response to systemic chemotherapy, radiotherapy, and
targeted therapy. As a result, CAFs response to treatment may diminish direct
anti-cancer drug efficiency by promoting cancer cells self-renewal and survival.
been associated with the activation of stress-associated mitogen-
activated protein kinase (MAPK) signaling pathway [Jun N-
terminal kinase (JNK) and P38 MAPK] (Toste et al., 2016).
Finally, the indirect effect of CT on CAFs secretome may also
occur due to the dysregulated crosstalk between cancer cells and
CAFs. For instance, Nab-paclitaxel treatment increases CXCL-
10 expression in pancreatic cancer cells, leading to lower IL-
6 secretion by CAFs subsequently impairing migration and
invasive capabilities of cancer cells (Feng et al., 2018).
Radiotherapy
Similarly to CT, radiotherapy (RT) has been reported to impact
the secretome of CAFs (Figure 3). Rødningen and colleagues
showed that ionizing radiation altered the fibroblasts expression
of genes involved in ECM remodeling as well as Wnt and
IGF signaling to support cancer stemness and resistance to
therapy (Rødningen et al., 2005; Wang Z. et al., 2019). Persistent
DNA damage, induction of senescence, and TGF-beta pathway
activation rather than cellular death are some of the proposed
mechanisms modulating CAFs secretome upon RT (Ansems and
Span, 2020). Importantly, a vast body of evidence suggests that
RT enhances paracrine signaling between fibroblasts and cancer
cells through the IGF and TGF-beta pathways (Barker et al.,
2015; Tommelein et al., 2018). Promotion of EMT, enhanced
cancer stemness properties, and increased resistance to therapy
are among the various effects exerted by RT-activated CAFs
(Arshad et al., 2015; Barker et al., 2015). For instance, IGF-1
activates the IGF-1R/AKT/mTOR survival pathway in CRC, and
CXCL-12 promotes EMT and invasion in pancreatic cancer (Li D.
et al., 2016; Tommelein et al., 2018). Alternatively, RT-activated
CAFs may also support intra-tumoral angiogenesis (Hellevik
et al., 2013). Interestingly, several studies have reported that
the immunoregulation exerted by CAFs remains unaltered after
ionizing RT (Hellevik et al., 2013; Gorchs et al., 2015; Berzaghi
et al., 2019). Thus, combination with immune-targeted therapies
may be an attractive clinical approach for RT-treated patients.
Targeted Therapy
Originally designed to be specific to cancer cells, targeted
therapies may also produce a range of undesirable off-target
effects on stromal cells and particularly on CAFs secretome. For
instance, specific secretion of HGF and neuregulin (NRG)-1 by
fibroblasts upon exposure to vemurafenib -a BRAF inhibitor-
was reported in melanoma (Fedorenko et al., 2015). Of note,
the activation of MET by HGF has been suggested as a potential
mechanism of acquired tyrosine kinase inhibitor (TKI) resistance
to gefitinib in epidermal growth factor receptor (EGFR)-mutant
non-small cell lung cancer (NSCLC) (Yano et al., 2008) and to
vemurafenib itself in BRAF-mutant melanoma (Wilson et al.,
2012). In PCa, HGF and NRG-1 have been identified as non-
cell-autonomous drivers of antiandrogen resistance. In this
setting, NRG-1/epidermal growth factor receptor 3 (HER-3)
signaling axis blockade demonstrated promising tumor growth
suppression (Zhang Z. et al., 2020). More recently, Hirata and
colleagues reported alternative CAF-induced resistance to BRAF
inhibition. In this setting, BRAF inhibitor reprograms CAFs
by enhancing platelet-derived growth factor receptor (PDGFR)
activity, thus increasing ECM production –thrombospondin
(THBS)-1/2, tenascin C (TNC), or POSTN, among other matrix
components– and stiffness to potentiate cancer cells tolerance to
treatment (Hirata et al., 2015). These data illustrate how CAFs
functions can be affected even by targeted therapies to enable the
emergence of resistance to treatment.
Epigenetic Regulation of CAFs Secretome
CAF phenotype may be driven by epigenetic deregulation rather
than by somatic mutations (Qiu et al., 2008; Bianchi-Frias
et al., 2016; Pidsley et al., 2018). DNA methylation, histone
modifications, chromatin remodeling, and non-coding RNA–
micro RNA (miRNA) and long non-coding RNA (lncRNA)–are
the well-described molecular mechanisms behind the epigenetic
CAF reprogramming and have been thoroughly reviewed
elsewhere (Marks et al., 2016; Melissari et al., 2020; Pan
and Zheng, 2020). Interestingly, several studies support the
hypothesis that an epigenetic switch would initiate the activation
process leading to a stable CAF cell state with tumor-supportive
secretory phenotype (Albrengues et al., 2015; Kalluri, 2016).
For instance, multiple genes coding for secreted factors, such
as IL-1a, CCL-5, and CCL-26; show differential hypomethylation
patterns in CAFs and are consequently overexpressed in
pancreatic cancer. In this case, paracrine lactate secreted by
PDAC cells leads to ten-eleven translocation (TET) enzyme
activation triggering the epigenomic reprogramming (Bhagat
et al., 2019). Remarkably, different epigenetic mechanisms
can merge into the same signaling cascade as happening
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for the STAT-3 pathway. Indeed, SOCS-1 methylation and
downregulation in PDAC-associated CAFs enhance STAT-3-
induced IGF-1 expression (Xiao et al., 2016) to promote the
survival and proliferation of pancreatic cancer cells (Kopantzev
et al., 2017). Alternatively, LIF-induced methylation of Shp-1
promoter abrogates its expression leading to a STAT-3-mediated
CAF pro-invasive phenotype (Albrengues et al., 2015).
In conclusion, in the absence of genomic mutations,
epigenetic alterations may be seen as key determinants of CAF
phenotype and could become promising targets for cancer
treatment. Importantly, several clinical trials are currently
exploring the benefits of DNA methylation therapies in
solid tumors including colorectal (NCT01896856), pancreatic
(NCT03264404), or prostate cancer (NCT03572387). Even
though cancer cells are the intended target, the above-
mentioned data suggest a potential effect of DNA methylation
therapies over CAFs that will need to be carefully assessed in
treated patients.
CAFS SECRETOME AS DETERMINANT OF
TUMOR DEVELOPMENT
Cancer Cells Self-Renewal
A vast body of evidence indicates that CAFs secretome may
contribute to tumor progression by enhancing cancer stemness
(Figure 4). Indeed, CAF-secreted IGF-2 as well as IL-6 and IL-
8 produced by CD-10+ GPR-77+ CAFs are promoting cancer
stemness and tumor formation in lung cancer (Chen et al., 2014;
Su et al., 2018). Similarly, PCa-derived CAFs with decreased
expression of AR promote stemness in cancer cells through IFN-
γ and M-CSF secretion (Liao et al., 2017). Importantly, cancer
stemness induced by CAF-secreted factors may involve different
pathways. For instance, PI3K/AKT pathway activation drives
the progression of anal squamous cell carcinoma through IGF-
2 secretion by the PDGFRB+ CAFs population (Cacheux et al.,
2019). Similarly, IGF-2-secreting CAFs promote tumor regrowth
and decreased latency after primary resection in CRC (Unger
et al., 2017). Alternatively, NOTCH signaling may be triggered
by CAF-derived CCL-2 to induce stem cell features as observed in
BC cells (Tsuyada et al., 2012). Finally, WNT signaling activation
by CAF-secreted HGF in colorectal adenocarcinomas or by CAF-
secreted POSTN in head and neck squamous cell carcinoma
and BC cells may also promote cancer stemness and further
metastatic initiation (Vermeulen et al., 2010; Malanchi et al.,
2011; Yu et al., 2018).
In addition to cytokine-driven signaling, cancer cells self-
renewal and aggressiveness may also depend on metabolic cues
originating from the TME (reviewed in Reina-Campos et al.,
2017; Li et al., 2020). Specifically, CAFs originating lactate and
glutamine production as well as autophagic alanine secretion are
sustaining cancer cells metabolism, stemness, and progression
to metastasis (Fiaschi et al., 2012; Curry et al., 2013; Sousa
et al., 2016; Yang L. et al., 2016). The specific mechanisms
enabling CAFs to deliver distinct nutrients to cancer cells are
being explored. However, CAFs response to the surrounding
constraints, such as the epigenetic reprogramming induced by
chronic hypoxia, is likely to play a relevant role in metabolic
reprogramming of CAFs (Becker et al., 2020).
Metastatic Cancer Cells Spreading
As mentioned above, CAF-secreted factors may also drive
cancer progression by enhancing the metastatic potential of
cancer cells (Figure 4). For instance, while TGF-beta activates
different genetic programs in a wide range of stroma cells,
the main contributor to its pro-tumorigenic influence seems
to be an autocrine loop maintaining the secretion of pro-
metastatic factors by CAFs (Calon et al., 2012). In addition,
CAF-secreted TGF-beta promotes paracrine reprogramming of
epithelial cancer cells by inducing EMT in tumors of distinct
origin (Zhuang et al., 2015). In CRC, TGF-beta induces IL-
13 expression in fibroblasts, and subsequent TGF-beta/IL-13
synergy activates an EMT program in epithelial cells (Scharl et al.,
2013). Alternatively, Calon and colleagues described TGF-beta-
activated CAFs secreting IL-6 and IL-11 leading to enhanced
STAT-3-dependent survival and spreading of metastatic CRC
cells (Calon et al., 2012). Similar observations were made in
gastric cancer where CAF-secreted IL-6 induced EMT and
metastasis through STAT-3 pathway activation (Wu et al.,
2017). Alternatively, CAF-secreted vascular cell adhesion protein
(VCAM)-1 has been shown to stimulate lung cancer cells
migration and invasion (Zhou et al., 2020).
Besides their autocrine and paracrine activities regulating
progression to metastasis, CAFs-secreted factors may also
support cancer spreading by influencing ECM deposition at both
the primary and metastatic sites. For example, Chakravarthy
and colleagues described that TGF-beta-activated CAFs could
induce the expression of large ECM components related to cancer
progression (Chakravarthy et al., 2018). In this regard, TGF-
beta-activated CAFs may secrete POSTN in order to increase
proliferation, motility, and invasive properties in head and neck
cancer (HNC) cells (Qin et al., 2016). Similarly, CAF-secreted
POSTN may also promote tumor progression in CRC through
YAP/TAZ activation in cancer cells (Ma et al., 2020). Of note,
Deng and colleagues showed that the YAP-activated Wnt/β-
catenin pathway promotes colon tumorigenesis (Deng et al.,
2018). Hence, the overall data suggest a complex paracrine
regulation of the Wnt pathway in cancer cells by TGF-beta-
activated CAFs through POSTN secretion and YAP activation in
order to enhance tumor progression and metastasis formation.
Immunomodulation
Somewhat contradictory evidences of CAFs immunoregulatory
functions have been described during cancer progression
(Figure 4). While increased abundance of CAFs clearly predicts
immune exclusion and immunotherapy failure, a complete
depletion of CAFs was associated with decreased intra-tumoral
immune infiltration (Özdemir et al., 2014; Chakravarthy et al.,
2018). One reason explaining opposite functions of CAFs in
modulating immune infiltration may reside in the fact that
different CAFs subpopulations with distinct properties are
coexisting inside the tumor. For example, among the four CAF
subsets identified in BC, only CAF-S1 subtype characterized by
high FAP expression promoted immunosuppression by secreting
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FIGURE 4 | CAFs secretome determines cancer progression. CAF-secreted factors regulate cancer development by enhancing directly epithelial cancer cells
self-renewal and aggressiveness. Alternatively, a range of CAF-secreted factors may support progression to metastasis by maintaining an immunosuppressive
environment or by enhancing pro-tumorigenic angiogenesis.
CXCL-12 and enhancing immunosuppressive T regulatory cells
(Treg) capacity to block T effector cells proliferation (Costa et al.,
2018). Importantly, FAP+ CAFs are also the main producers
of CXCL-12 in PDAC, and their specific depletion increases
immunological control over tumor growth (Kraman et al., 2010;
Feig et al., 2013). In this setting, the decreased expression of
CXCL-12 leads to intra-tumoral T cell accumulation, which in
turn synergizes with immuno- or chemotherapy to reduce cancer
cells abundance (Feig et al., 2013; Sherman et al., 2014).
In addition to CXCL-12, a wide range of CAF-
produced chemokines has been associated with tumor
immunosuppression. For example, CAF-secreted CCL-5
induces CD4+CD25+ Treg cells in BC (Tan et al., 2011; Costa
et al., 2018). Notably, CCL-5 dependent Treg cells recruitment
was associated with lung metastasis in BC mouse model (Tan
et al., 2011). CAFs also participate in immunosuppressive
myeloid cell recruitment and differentiation by secreting SDF-1
to attract monocytes and to induce their differentiation into
myeloid-derived suppressor cells (MDSCs) contributing to
cancer immune evasion (Gabrilovich and Nagaraj, 2009; Deng
et al., 2017). Alternatively, Wang and colleagues showed that
CAF-secreted POSTN promoted MDSCs infiltration to establish
a pre-metastatic niche during breast tumor metastasis through
AKT and STAT-3 pathway activation (Wang Z. et al., 2016).
Similarly, FAP+ CAF-secreted CCL-2 mediates STAT-3 pathway
activation in MDSC to promote liver tumor growth and to
suppress T cells proliferation during colorectal carcinogenesis
(Chun et al., 2015; Yang et al., 2016). Alternatively, CAF-secreted
IL-6 and IL-8 may promote monocytes differentiation into M2
macrophages and further recruitment in the tumor to diminish
natural killer (NK) cells cytotoxicity against CRC cells (Cho
et al., 2018; Zhang et al., 2019). Finally, CAFs may directly
interfere with NK anti-tumoral functions through prostaglandin
E2 (PGE2) secretion or MMPs production decreasing NK
receptor ligands expression in tumor cells, thus reducing NK
receptor-dependent cytotoxic activity (Balsamo et al., 2009; Ziani
et al., 2017).
As mentioned earlier, CAFs are major producers of TGF-
beta, a key contributor to tumor immunosuppression (Calon
et al., 2015; Batlle and Massagué, 2019). For instance, TGF-beta
produced by CAFs was correlated with CD8+ T cells exclusion,
which in turn has been associated with resistance to anti-
PD-L1 antibody-based immune checkpoint inhibitor therapy
(Mariathasan et al., 2018). In this context, TGF-beta pathway
blockade through TGF-beta receptor (TGFBR)-1 inhibition or
TGF-beta blocking antibody enabled T cells infiltration into
the tumor, restoring the anti-tumor immunity induced by
the anti-PD-L1 antibody in BC and CRC pre-clinical models
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(Mariathasan et al., 2018; Tauriello et al., 2018). In contrast,
TGFBR-2 deletion in BC induces MDSCs recruitment to the
TME, reducing T cell proliferation and activation (Yang et al.,
2008). Interestingly, TGFBR-2 deletion has been associated
with the increased expression of stromal TGF-beta leading
to MDSCs recruitment of indifferent cancers including HNC
or PCa (Lu et al., 2006; Franco et al., 2011). These data
suggest that the genetic ablation of TGFBR-2 enhances the
secondary activation of TGF-beta that may indirectly promote
intra-tumoral immunosuppression.
Angiogenesis
Neovascularization is an important process during
tumorigenesis. Interestingly, CAFs are the main source of
VEGF-A, the most potent pro-angiogenic factor, which binds
to its cognate VEGF receptor (VEGFR)-2 expressed on
endothelial cells (Figure 4) (Fukumura et al., 1998; Apte et al.,
2019). Noma and colleagues showed that TGF-beta pathway
activation in CAFs was essential to induce VEGF secretion
(Noma et al., 2008). In addition, Sánchez-Elsner and colleagues
demonstrated a synergistic cooperation between SMADs and
hypoxia-inducible factor (HIF)-1 alpha proteins to drive VEGF
expression, suggesting a potential link between TGF-beta
pathway and hypoxia to promote tumor angiogenesis (Sánchez-
Elsner et al., 2001). Nevertheless, there is controversial evidence
about the role of TGF-beta in tumor angiogenesis suggesting
a differential expression of TGF-beta ligands during different
phases of angiogenesis (Pardali et al., 2010). For instance, Liu
and colleagues showed that TGFBR-1 inhibitor and VEGF
synergistically induced tumor angiogenesis through α5-integrin
upregulation (Liu et al., 2009). In contrast, TGF-beta-TGFBR-1
signaling has been involved in the promotion of BC angiogenesis
through MMP-9 upregulation and through CAF-secreted
TGF-beta and SDF-1 in HCCs (Safina et al., 2007; Yang J. et al.,
2016).
In addition to promoting VEGF-dependent angiogenesis,
CAFs may enhance tumor angiogenesis through additional
paracrine signaling between stromal and cancer cells (Orimo
et al., 2005; Unterleuthner et al., 2020). For instance, CAF-
derived CXCL-12 leads to CXCL-8 secretion by PDAC
cells inducing new vessel formation by endothelial cells
(Matsuo et al., 2009). Alternatively, CAF-secreted galectin-
1 induces VEGF-A production by BC cells to promote
tumor angiogenesis (Tang et al., 2016). FGF has also been
recognized as a potent pro-angiogenic factor involved in tumor
angiogenesis (Compagni et al., 2000). Correspondingly, Pietras
and colleagues demonstrated that cervical carcinoma-derived
CAFs are secreting FGF-7 and FGF-2, inducing both epithelial
proliferation and tumor angiogenesis (Pietras et al., 2008).
Finally, CAFs not only are directly promoting tumor
angiogenesis by secreting pro-angiogenic factors but also act
indirectly by participating in ECM remodeling (Figure 4)
(De Palma et al., 2017). For example, CAFs may support
vascularization through biomechanical activity and ECM
stiffness promoted by MMP activity (Bordeleau et al., 2017;
Sewell-Loftin et al., 2017). Importantly, CAFs are the most
important suppliers of ECM-associated proteins essential to
vascular formation including TNC production resulting in
pro-angiogenic paracrine signaling (Newman et al., 2011; Rupp
et al., 2016).
Resistance to Anti-cancer Therapy
In addition to modulating tumor progression, CAFs secretome
may also promote resistance to systemic and targeted therapies.
For instance, CAF-secreted SDF-1 upregulates the expression
of special AT-rich sequence-binding protein-1 (SATB-1) in
pancreatic cancer cells, which not only sustains pancreatic tumor
growth but also mediates gemcitabine resistance (Wei et al.,
2018). Furthermore, CAF-derived IGF-1 and IGF-2 induce CT
resistance in pancreatic cancer (Ireland et al., 2016). IGF-2 also
increases insulin receptor/IGF 1 receptor (IGF1R) axis activation
in cancer cells to enhance resistance to anti-EGFR-targeted
therapy in cholangiocarcinoma (Vaquero et al., 2018). In the
same line, fibroblast-secreted HGF activates both the MAPK and
PI3K/AKT pathways contributing to BRAF-targeted therapies’
primary resistance in melanoma and in a subset of colorectal and
glioblastoma cancer cells (Straussman et al., 2012).
Regarding hormonotherapy, CAFs-secreted factors contribute
to estrogen receptor alpha (ER-α) phosphorylation in BC cells,
thereby promoting tamoxifen resistance (Pontiggia et al., 2012).
In addition, Li and colleagues reported that letrozole, an
aromatase inhibitor lowering estrogen production, had opposite
functional effects on CAFs secretome (Li K. et al., 2016).
Letrozole reduces CCL-2, CCL-5, and CXCL-1 expression in
CAFs, possibly contributing to its efficacy against BC cells.
Conversely, letrozole also increases CAFs secretion of POSTN, a
factor involved in BC progression and metastasis (Kyutoku et al.,
2011; Li K. et al., 2016). In PCa, Zhang and colleagues, described
that CAF-secreted NRG-1 activates the HER-3 signaling pathway
leading to resistance to antiandrogen therapy (Zhang Z. et al.,
2020). Notably, NRG-1 expression in PCa-derived CAFs is
increased after antiandrogen therapy that may contribute to
potentiate resistance to treatment (Zhang Z. et al., 2020).
Consequently, the presence in the tumor of a range of secreted
factors involved in resistance to therapy may be the result
of CAFs’ own response to anti-cancer treatment. Indeed, CT
induces senescence-associated secretory phenotype in fibroblasts,
typically characterized by the increased secretion of cytokines,
chemokines, and growth factors previously associated with tumor
progression and treatment resistance (Demaria et al., 2017).
More specifically, Sun and colleagues demonstrated that primary
prostate fibroblasts increased WNT-16B expression in response
to CT. In this setting,WNT-16B enhanced prostate tumor growth
and diminished CT cytotoxicity against cancer cells (Sun et al.,
2012). Finally, previously mentioned IL-11 secreted by CAFs
upon cisplatin-based CT induced STAT-3 pathway activation and
chemoresistance in lung cancer cells (Tao et al., 2016).
PROGNOSTIC AND PREDICTIVE VALUE
OF CAFS SECRETOME
The identification of tumor features predicting prognosis, risk
of relapse, and benefit from treatment is absolutely essential
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for clinical decision-making in oncology. In this sense, a better
understanding of the TME has provided multiple prognostic
and diagnostic biomarkers in cancers of distinct origin (Bremnes
et al., 2011). For instance, CAFs biomarkers (Ha et al., 2014;
Dourado et al., 2018), tumor:stroma ratio quantification (Kemi
et al., 2018; Vangangelt et al., 2018), and stromal gene expression
profiling (Finak et al., 2008; Frings et al., 2013; Calon et al.,
2015) are powerful tools predicting clinical outcome. However,
addressing the exclusive impact of CAFs secretome on cancer
prognosis remains amajor challenge, and to our knowledge, there
is no example of CAF-secreted biomarkers currently applied to
the clinical setting.
Cytokines and chemokines have been proposed as prognostic
factors in different types of cancer. Yet, their pleiotropic nature
and multiple cellular origin as well as their distinct releasing
patterns make their use as biomarkers especially challenging.
Circulating IL-6 has been associated with cancer progression
and poor prognosis in melanoma, BC, and gastrointestinal
tumors, among others (Salgado et al., 2003; Hoejberg et al.,
2012; Vainer et al., 2018), but only few studies have assessed
IL-6 cellular origin. In bladder cancer patients for instance,
CAF-derived IL-6 and ACTA-2 (αSMA coding gene) co-
upregulation correlated with poor survival (Goulet et al., 2019).
In esophageal adenocarcinoma, although IL-6 serum levels did
not correlate with patients’ outcome, the expression of ADAM-
12, a surrogate marker for IL-6-producing CAFs, predicted
poor prognosis after neoadjuvant chemoradiation (Ebbing et al.,
2019). CXCL chemokines are additional examples of promising
prognosis biomarkers associated with CAFs functions. Indeed,
CAF-derived CXCL-14 expression was correlated with shorter
recurrence-free survival in estrogen receptor negative, triple
negative, and basal-like BC (Sjöberg et al., 2016), as well
as in additional tumor types (reviewed in Westrich et al.,
2020). Similarly, CXCL-1 and CXCL-8 positivity in CAFs was
significantly associated with poor prognosis in gastric cancer
patients (Naito et al., 2019), whereas CXCL-8,−10, and−11 CAFs
expression correlated with resistance to neoadjuvant CT and
poor prognosis in BC (Xu et al., 2020).
As previously mentioned, CAFs-secreted growth factors, such
as HGF or IGFs, are involved in resistance to targeted therapy
and may be of use to predict response to treatment. Indeed,
HGF expression was correlated with innate resistance to BRAF
inhibition, and increased HGF plasma levels predicted worse
overall survival (OS) and progression-free survival (PFS) in
BRAF-mutant melanoma patients (Straussman et al., 2012;
Wilson et al., 2012). Alternatively, CAF-secreted IGF-binding
proteins have been proposed as a potential therapeutic target and
prognostic biomarker in pancreatic cancer and other tumor types
(Thomas and Radhakrishnan, 2020).
Additional CAFs-secreted proteins, such as VCAM-1, THBS-
2, and POSTN, involved in cancer progression were recently
evaluated as potential actionable biomarkers. In lung cancer, the
soluble fraction of VCAM-1 predicted relapse and lower OS,
whereas high POSTN expression was associated with shorter PFS
in ovarian cancer patients (Ryner et al., 2015; Zhou et al., 2020).
Of note, a recent meta-analysis confirmed the value of POSTN
as a biomarker predicting poor outcome in different solid tumors
(Yang et al., 2020). Finally, increased THBS-2 predicted decreased
OS in CRC patients (Wang X. et al., 2016).
CAF-derived exosomes transferring miRNA (Au Yeung et al.,
2016; Fang et al., 2019; Qin et al., 2019) and lncRNA (Qu et al.,
2016) to tumor cells have been reported to promote treatment
resistance in different tumor types and were also evaluated as
potential predictive biomarkers. In this context, serum detection
of plasma exosomal miR-196a levels correlated with tumor size,
lymph nodemetastasis, advanced tumor stage, and poor OSwhile
accurately discriminating chemoresistant and sensitive patients
in HNC (Qin et al., 2019). Of note, suppressing or interfering
with CAF-derived exosomes transference to cancer cells has been
proposed as a novel therapeutic approach (Li et al., 2017).
Similarly to soluble factors, many ECM-related products are
contributing to the predictive power of stromal-originating gene
signatures (Andriani et al., 2018; Yuzhalin et al., 2018; Jiang
et al., 2019). ECM remodeling enzymes, such as MMPs and tissue
inhibitors of MMP (TIMP), which are not exclusively but mainly
released by CAFs, have also been suggested to predict cancer
progression and response to treatment (Liu et al., 2019). Among
them, Eiró et al. assessed the potential influence over patients’
prognosis of TIMP-2 expression by CAFs at the tumor center
and the invasive front of early stage BC. TIMP-2 resulted to be
a potent poor outcome predictor at both locations (Eiró et al.,
2015). Many members of the MMP family promoting tumor
invasion through ECM degradation are also impacting cancer
prognosis. For instance, increased MMP-1 expression by CAFs
was associated with high risk of relapse in stage II CRC, and
CAFs expression ofMMP-9,−11, and−13 correlated with shorter
relapse-free survival in BC (González et al., 2009; Eiro et al.,
2019). Remarkably, the relevance of MMPs for prognosis might
be cancer specific, as illustrated by MMP-2, which predicts poor
OS and PFS in NSCLC but associates with better survival in
patients with high grade BC (Leinonen et al., 2008; Niemiec et al.,
2013).
Along this line, other CAF-secreted ECM components,
such as collagens, have been recently recognized as important
contributors to cancer progression and as potential liquid
biopsy biomarkers in different tumor types (Giussani et al.,
2019). Serum level of PRO-C3 –a biomarker of collagen III
production– is a promising example predicting poor OS in
PDAC patients and may be a non-invasive actionable biomarker
for desmoplasia-targeting therapies (Willumsen et al., 2019).
Interestingly and probably due to TGF-beta capacity to stimulate
collagens production by CAFs, serum levels of collagen fragments
have been associated with response to TGF-beta-targeted therapy
(Nissen et al., 2019).
Overall, these exciting findings are calling for further
validation of CAF-derived biomarkers in order to improve the
standard of care and decision-making in oncology. However,
it is worth noting that methodological variability will be
especially relevant when transferring biomarkers from bench to
bedside. Indeed, evaluating either a single or a panel of factors
through distinct techniques may complicate the validation of
CAFs secretome-based prognostic and predictive tools in the
clinical setting (Paulsson and Micke, 2014). Spatial and temporal
heterogeneity (see the Determinants of CAFs Secretome section)
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may be an additional issue that could be overcome by liquid
biopsy, a non-invasive method allowing real-time evaluation
of CAF-secreted biomarkers circulating in the bloodstream
(Herrera et al., 2019).
CAF-SECRETED FACTORS AS A
THERAPEUTIC TARGET
Targeting the CAFs Secretome Regulating
Cancer Cells Proliferation
Since CAFs complete depletion or blockade of fibroblast-
rich tumor stroma formation resulted in decreased anti-
tumor immune infiltration and more aggressive tumors, recent
strategies have rather focused on the regulation of CAFs
originating paracrine and autocrine signaling (Özdemir et al.,
2014; Rhim et al., 2014). For instance, CAFs reprogramming by
vitamin A and vitamin D was shown to inhibit tumor-supportive
secretome associated with cancer progression (Froeling et al.,
2011; Sherman et al., 2014). Remarkably, gemcitabine and either
vitamin A or vitamin D regimen resulted in significant tumor
burden reduction in PDAC pre-clinical models (Sherman et al.,
2014; Carapuça et al., 2016). Hence, a phase II trial is currently
evaluating the combination of CT and vitamin D in PDAC
patients (NCT03415854). Yet, a previous phase II trial did
not show any survival benefit with high doses of vitamin D3
compared with standard doses in combination with CT in
metastatic CRC patients (Ng et al., 2019).
Importantly, vitamin A and vitamin D reprograming
strategies are both associated with TGF-beta –a key autocrine
and paracrine mediator of CAFs signaling– pathway inhibition.
Indeed, vitamin D receptor ligands decrease fibroblast activation
by TGF-beta (Ding et al., 2013), whereas all-trans retinoic
acid (ATRA) –the active metabolite of vitamin A– inhibits the
fibroblasts capacity to release active TGF-beta, thus impeding
autocrine TGF-beta activation (Sarper et al., 2016). Of note,
ATRA reprogramed fibroblasts are in addition reducing Wnt–β-
catenin signaling in the surrounding cancer cells through SFRP-4
secretion (Froeling et al., 2011).
TGF-beta has emerged as a potential therapeutic target in
oncology. Notably, TGF-beta inhibitor in combination with
gemcitabine improved the OS in locally advanced and metastatic
PDAC patients (Melisi et al., 2018). A phase I/II trial is currently
testing the ability of TGF-beta inhibitor to restore the sensitivity
to CT in patients with TGF-beta-activated program in metastatic
CRC resistant to CT (NCT03470350). The analysis of the TGF-
beta-activated program in CAFs provided several additional
therapeutic targets. Among them, IL-6 and IL-11 are secreted
interleukins activating STAT-3-dependent survival and spreading
of metastatic CRC cancer cells (Calon et al., 2012). IL-11 or IL-
6 inhibitors displayed potent anti-cancer activity in pre-clinical
models of cancer of distinct origins (Coward et al., 2011; Putoczki
et al., 2013; Song et al., 2014). Siltuximab, an IL-6 inhibitor, did
not show benefit as monotherapy in CT-pretreated castration-
resistance PCa patients (Dorff et al., 2010). However, additional
IL-6 pathway inhibitors are currently tested in combination
with CT in patients with breast (NCT03135171), pancreatic
(NCT04258150, NCT02767557), or liver cancer (NCT04338685).
Among CAF-secreted molecules, ECM components have also
raised special interest as therapeutic targets. Yet, clinical trials
failed to demonstrate the clinical benefit from COL-3, MMP-2,
and MMP-9 inhibitors in patients (Chu et al., 2007). Similarly,
PEGPH20, a PEGylated recombinant human hyaluronidase, did
not add benefit to standard CT in PDAC patients (Tempero et al.,
2020).
Off-target effects and indirect resistance to treatment
involving CAFs functions may explain the lack of benefit of
current stroma-targeting therapies. For example, Casanovas
and colleagues described that VEGFR blockade induces tumor
hypoxia and paradoxically triggers pro-angiogenic factors
production, such as FGF family members (Casanovas et al.,
2005). Likewise, CAFs derived from anti-VEGF-resistant tumors
are secreting PDGF-C in order to reactivate tumor angiogenesis
(Crawford et al., 2009). A potential solution may come from
multi-targeted therapies, such as nintedanib, a triple angiokinase
inhibitor blocking VEGFR, FGFR, and PDGFR. Nintedanib
reduces the CAFs expression of IL-6, IL-8, VEGF, and VCAM-
1 as well as OPN and showed important clinical benefit in
combination with CT in NSCLC patients (Hilberg et al., 2008;
Reck et al., 2014; Yamanaka et al., 2020).
Overcoming CAFs-Induced
Immunosuppression
Several preclinical studies have recently underscored the
relevance of TGFBR-1 targeting in order to activate an anti-
tumor immune response. TGFBR-1 inhibitor (galunisertib) and
anti-PD-L1 combination treatment increased intra-tumoral T
cell infiltration and activation, thereby promoting a potent
anti-tumor response in CRC and BC pre-clinical models.
Characteristically, this effect was associated with a reduction
of fibroblasts activation and an increased anti-tumor immune
genes expression (Holmgaard et al., 2018; Mariathasan et al.,
2018; Tauriello et al., 2018). Curiously, anti-PD-L1 treatment
alone enhanced the expression of TGF-beta activated CAFs
biomarkers, suggesting that TGF-beta pathway inhibition is
essential to enhance anti-PD-L1 therapy (Holmgaard et al.,
2018). In this context, two phase I trials are being conducted to
evaluate the benefit of galunisertib in combination with immune
checkpoint inhibitors (anti-PD-1, anti-PD-L1) in refractory
metastatic cancer patients (NCT02423343, NCT02734160). In
contrast, Zhao and colleagues showed that another TGFBR-1
inhibitor (TEW-7197) failed to increase anti-PD-L1 treatment
efficacy in melanoma mouse model. TEW-7197 promoted
fibroblasts proliferation and diminished PD-L1 expression in
cancer cells throughMMP-9 secretion by CAFs. Interestingly, the
authors reported increased TGFBR-2 expression upon treatment
(Zhao et al., 2018). In this context, previouslymentioned TGFBR-
2-induced secondary activation of TGF-beta could potentially
contribute to CAFs activation and to combination treatment
failure (Lu et al., 2006; Franco et al., 2011).
Bintrafusp alfa, a bi-functional fusion protein composed
of an anti-PD-L1 antibody and a TGF-beta “trap,” was
recently designed to potentiate immune checkpoint and
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TGF-beta inhibitors regimen. Bintrafusp alfa induces tumor
regression and decreased spontaneous metastasis in a CRC
mouse model by activating CD8+ T cells and NK cells
while abrogating CAFs activation in the tumor (Lan et al.,
2018). Clinical benefit of bintrafusp alfa is currently under
evaluation in several cancer patients’ trials including NSCLC
(NCT03840902), BC (NCT03579472), HNSCC (NCT04247282),
and CRC (NCT03436563).
Remarkably, previously mentioned ATRA-mediated CAFs
reprograming increases T cells infiltration in PDAC while
blocking CAFs autocrine TGF-beta activation (Ene-Obong et al.,
2013; Sarper et al., 2016). In view of the above-mentioned data
on TGF-beta inhibition, pancreatic cancer patients who will be
treated with ATRA (NCT04241276) may as well benefit from
combination regimen with immune checkpoint inhibitors.
Finally, CAF-secreted factors, such as FN and TNC, have
been targeted for antibody-based delivery of immune enhancers
specifically to the tumor site in order to concentrate their
effect on cancer tissue and decrease treatment-associated toxicity
on healthy tissue (Pasche and Neri, 2012). For example, L19-
TNF and L19-IL-2 immunocytokines conjugate an antibody-
recognizing FN with cytokines (TNF-α and IL-2, respectively)
(Neri, 2019). Preclinical data already suggested the robust
anti-cancer potential of L19-based immunocytokines (Lieverse
et al., 2020), and phase II and III trials are currently
testing the clinical benefit of L19-TNF-a and L19-IL-2 in
patients with soft tissue sarcoma (NCT03420014) or melanoma
(NCT02938299, NCT03567889).
CONCLUSIONS
From a general perspective, CAFs should be considered
as a heterogeneous and dynamic stromal component which
evolution to distinct functional subpopulations is paralleling
the tumorigenic process. Spatio-temporally regulated factors
and crosstalk with other TME components drive this co-
evolution from local tissue resident fibroblasts and other
cell types to distinct CAFs subtypes. Indeed, the intra-
tumoral location effect over CAFs function is determined by
spatial distribution of tumor cell-derived factors (Figure 1).
Among them, autocrine or paracrine communications and EVs
interchange have been described to define CAF phenotypes.
However, the influence of other cell populations–infiltrating
immune cells, endothelial cells–, and biomechanical stress (ECM
stiffness) also differentially distributed within the TME may
play an important role in modulating CAFs behavior. Among
other potential functions associated with CAFs, there is solid
evidence of several well-defined cell sub-specializations with
either contractile and ECM remodeling functions or secretory
and immunomodulating functions (Figure 2).
The potential role of CAFs secretome for predicting patient’s
outcome and response to treatment has also been intensively
investigated. Overall findings illustrate the potential benefit of
using CAFs secretome biomarkers to improve patient’s selection
and treatment follow-up. Notwithstanding their potential
as actionable biomarkers, current knowledge is still mostly
providing descriptive information of individual secreted factors
but does not advocate for their translation into the clinical setting.
Comprehensive -omics analyses are currently being used for
an extensive characterization of CAFs secretome in order to
discover and validate robust biomarkers and novel targets within
the stroma (Principe et al., 2018). In this sense, liquid biopsy
appears to be a promising method for real-time evaluation of the
different components of CAFs secretome, allowing the detection
of CAF-derived soluble factors, CAF-derived exosomes, and even
circulating CAFs as potential biomarkers (Herrera et al., 2019).
Recent findings suggest a clear impact of both systemic
and targeted anti-cancer therapies upon CAFs secretome that
will need to be carefully assessed in view of patients’ response
to treatment (Figure 3). Understanding the impact of CAFs
secretome on treatment resistance after therapy exposure will
provide original tools to monitor patient’s response. The
implementation of clinical criteria evaluating components of
the CAFs secretome will help in refining patients’ selection for
suitable therapies and improve oncological outcomes.
While CAFs contribution over tumor development is still a
matter of research, CAFs secretome has already demonstrated its
potential as a target for original therapeutic strategies in a wide
range of cancers (Figure 4). However, a better understanding
of CAFs secretome has also underscored the importance of
defining the cell-type specific response to secreted factors.
For instance, TGF-beta is a pro-metastatic cytokine currently
targeted inmultiple clinical trials (NCT04031872, NCT02452008,
NCT03834662, NCT04574583). Yet, TGF-beta is also considered
as a tumor suppressor due to its cytostatic effect on cancer
cells (Akhurst and Hata, 2012). Another example is IL-11, a
pro-metastatic factor that can be successfully targeted by IL-
11 signaling antagonist to reduce cancer progression (Putoczki
et al., 2013). Until recently, IL-11 was better known for its
capacity to stimulate platelet production, and for decades, cancer
patients have been treated with rhIL-11 to overcome CT-induced
thrombocytopenia (Isaacs et al., 1997; Cairo et al., 2005;Wu et al.,
2012). These findings underscore the importance of carefully
assessing every cell-type specific response to secreted factors
before therapeutic translation into the clinical setting.
CAFs may not be understood and targeted as a unique family
anymore, and a detailed definition of CAFs secretome is still
an unmet need. For instance, CAFs and senescent fibroblasts
coexisting within the TME are able to secrete equivalent factors.
Hence, CAFs secretome and senescence-associated secretory
phenotype (SASP) may have overlapping tumor-promoting
effects (Sahai et al., 2020).
Different treatment strategies, such as targeting a specific
functional subtype of CAFs, reprogramming CAFs backwards
to a tumor-suppressor phenotype, or even switching between
distinct functional subtypes, are currently being addressed.
Along this line, a major challenge in precisely defining CAFs
heterogeneity and therapeutically targeting CAFs secretome
will reside in a better comprehension of CAFs spatiotemporal
evolution during tumor progression.
Overall, it is reasonable to believe that increasing our
understanding of CAFs inter- and intra-tumoral heterogeneity
will be key to fully grasp CAFs secretome diverseness and
potentiate anti-cancer therapy.
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grade and matrix metalloproteinase 2 expression in stromal fibroblasts help
to stratify the high-risk group of patients with early breast cancer identified
on the basis of St gallen recommendations. Clin. Breast Cancer 13, 119–128.
doi: 10.1016/j.clbc.2012.12.005
Nissen, N. I., Karsdal, M., and Willumsen, N. (2019). Collagens and cancer
associated fibroblasts in the reactive stroma and its relation to cancer biology. J.
Exp. Clin. Cancer Res. 38:115. doi: 10.1186/s13046-019-1110-6
Noma, K., Smalley, K. S. M., Lioni, M., Naomoto, Y., Tanaka, N., El-Deiry,
W., et al. (2008). The essential role of fibroblasts in esophageal squamous
cell carcinoma-induced angiogenesis. Gastroenterology 134, 1981–1993.
doi: 10.1053/j.gastro.2008.02.061
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-
Sarvise, M., et al. (2017). Distinct populations of inflammatory fibroblasts
and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596.
doi: 10.1084/jem.20162024
Olapade-Olaopa, E. O., MacKay, E. H., Taub, N. A., Sandhu, D. P. S., Terry, T.
R., and Habib, F. K. (1999). Malignant transformation of human prostatic
epithelium is associated with the loss of androgen receptor immunoreactivity
in the surrounding stroma. Clin. Cancer Res. 5, 569–576.
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T.,
Naeem, R., et al. (2005). Stromal fibroblasts present in invasive human breast
carcinomas promote tumor growth and angiogenesis through elevated SDF-
1/CXCL12 secretion. Cell 121, 335–348. doi: 10.1016/j.cell.2005.02.034
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C. C.,
Simpson, T. R., et al. (2014). Depletion of carcinoma-associated fibroblasts
and fibrosis induces immunosuppression and accelerates pancreas cancer with
reduced survival. Cancer Cell 25, 719–734. doi: 10.1016/j.ccr.2014.04.005
Pan, X., and Zheng, L. (2020). Epigenetics in modulating immune functions of
stromal and immune cells in the tumormicroenvironment.Cell. Mol. Immunol.
17, 940–953. doi: 10.1038/s41423-020-0505-9
Pardali, E., Goumans, M. J., and ten Dijke, P. (2010). Signaling by members of
the TGF-β family in vascular morphogenesis and disease. Trends Cell Biol. 20,
556–567. doi: 10.1016/j.tcb.2010.06.006
Pasche, N., and Neri, D. (2012). Immunocytokines: a novel class of potent armed
antibodies. Drug Discov. Today 17, 583–590. doi: 10.1016/j.drudis.2012.01.007
Paulsson, J., and Micke, P. (2014). Prognostic relevance of cancer-
associated fibroblasts in human cancer. Semin. Cancer Biol. 25, 61–68.
doi: 10.1016/j.semcancer.2014.02.006
Pelon, F., Bourachot, B., Kieffer, Y., Magagna, I., Mermet-Meillon, F., Bonnet, I.,
et al. (2020). Cancer-associated fibroblast heterogeneity in axillary lymph nodes
drives metastases in breast cancer through complementary mechanisms. Nat.
Commun. 11:404. doi: 10.1038/s41467-019-14134-w
Pidsley, R., Lawrence, M. G., Zotenko, E., Niranjan, B., Statham, A., Song, J., et al.
(2018). Enduring epigenetic landmarks define the cancer microenvironment.
Genome Res. 28, 625–638. doi: 10.1101/gr.229070.117
Pietras, K., Pahler, J., Bergers, G., and Hanahan, D. (2008). Functions
of paracrine PDGF signaling in the proangiogenic tumor
stroma revealed by pharmacological targeting. PLoS Med. 5:e19.
doi: 10.1371/journal.pmed.0050019
Pontiggia, O., Sampayo, R., Raffo, D., Motter, A., Xu, R., Bissell, M. J., et al. (2012).
The tumormicroenvironmentmodulates tamoxifen resistance in breast cancer:
a role for soluble stromal factors and fibronectin through β1 integrin. Breast
Cancer Res. Treat. 133, 459–471. doi: 10.1007/s10549-011-1766-x
Principe, S., Mejia-Guerrero, S., Ignatchenko, V., Sinha, A., Ignatchenko, A., Shi,
W., et al. (2018). Proteomic analysis of cancer-associated fibroblasts reveals a
paracrine role for MFAP5 in human oral tongue squamous cell carcinoma. J.
Proteome Res. 17, 2045–2059. doi: 10.1021/acs.jproteome.7b00925
Putoczki, T. L., Thiem, S., Loving, A., Busuttil, R. A., Wilson, N. J., Ziegler, P.
K., et al. (2013). Interleukin-11 is the dominant Il-6 family cytokine during
gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell
24, 257–271. doi: 10.1016/j.ccr.2013.06.017
Qin, X., Guo, H., Wang, X., Zhu, X., Yan, M., Wang, X., et al. (2019).
Exosomal miR-196a derived from cancer-associated fibroblasts confers
cisplatin resistance in head and neck cancer through targeting CDKN1B and
ING5. Genome Biol. 20:12. doi: 10.1186/s13059-018-1604-0
Qin, X., Yan,M., Zhang, J.,Wang, X., Shen, Z., Lv, Z., et al. (2016). TGFβ3-mediated
induction of Periostin facilitates head and neck cancer growth and is associated
with metastasis. Sci. Rep. 6:20587. doi: 10.1038/srep20587
Qiu, W., Hu, M., Sridhar, A., Opeskin, K., Fox, S., Shipitsin, M., et al. (2008). No
evidence of clonal somatic genetic alterations in cancer-associated fibroblasts
from human breast and ovarian carcinomas. Nat. Genet. 40, 650–655.
doi: 10.1038/ng.117
Qu, L., Ding, J., Chen, C., Wu, Z. J., Liu, B., Gao, Y., et al. (2016). Exosome-t
lncARSR promotes sunitinib resistance in renal cancer by acting as a competing
endogenous RNA. Cancer Cell 29, 653–668. doi: 10.1016/j.ccell.2016.03.004
Rai, A., Greening, D. W., Chen, M., Xu, R., Ji, H., and Simpson, R.
J. (2019). Exosomes derived from human primary and metastatic
colorectal cancer cells contribute to functional heterogeneity of activated
fibroblasts by reprogramming their proteome. Proteomics 19:e800148.
doi: 10.1002/pmic.201800148
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J. Y., Orlov, S., Krzakowski,
M., et al. (2014). Docetaxel plus nintedanib versus docetaxel plus placebo in
patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a
phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15, 143–155.
doi: 10.1016/S1470-2045(13)70586-2
Reina-Campos, M., Moscat, J., and Diaz-Meco, M. (2017). Metabolism
shapes the tumor microenvironment. Curr. Opin. Cell Biol. 48, 47–53.
doi: 10.1016/j.ceb.2017.05.006
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C.
F., Sastra, S. A., et al. (2014). Stromal elements act to restrain, rather
than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735–747.
doi: 10.1016/j.ccr.2014.04.021
Rødningen, O., Overgaard, J., Alsner, J., Hastie, T., and Børresen-Dale, A. L. (2005).
Microarray analysis of the transcriptional responseto single or multiple doses
of ionizing radiation in human subcutaneous fibroblasts. Radiother. Oncol. 77,
231–240. doi: 10.1016/j.radonc.2005.09.020
Rothenberger, N. J., Somasundaram, A., and Stabile, L. P. (2018). The role of
the estrogen pathway in the tumor microenvironment. Int. J. Mol. Sci. 19:611.
doi: 10.3390/ijms19020611
Rupp, T., Langlois, B., Koczorowska, M. M., Radwanska, A., Sun, Z., Hussenet,
T., et al. (2016). Tenascin-C orchestrates glioblastoma angiogenesis by
modulation of pro- and anti-angiogenic signaling. Cell Rep. 17, 2607–2619.
doi: 10.1016/j.celrep.2016.11.012
Ryner, L., Guan, Y., Firestein, R., Xiao, Y., Choi, Y., Rabe, C., et al.
(2015). Upregulation of periostin and reactive stroma is associated with
primary chemoresistance and predicts clinical outcomes in epithelial ovarian
cancer. Clin. Cancer Res. 21, 2941–2951. doi: 10.1158/1078-0432.CCR-
14-3111
Safina, A., Vandette, E., and Bakin, A. V. (2007). ALK5 promotes tumor
angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells.
Oncogene 26, 2407–2422. doi: 10.1038/sj.onc.1210046
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans,
R. M., et al. (2020). A framework for advancing our understanding
of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174–186.
doi: 10.1038/s41568-019-0238-1
Salgado, R., Junius, S., Benoy, I., van Dam, P., Vermeulen, P., Van Marck, E., et al.
(2003). Circulating interleukin-6 predicts survival in patients with metastatic
breast cancer. Int. J. Cancer 103, 642–646. doi: 10.1002/ijc.10833
Sánchez-Elsner, T., Botella, L. M., Velasco, B., Corb,í, A., Attisano, L.,
and Bernabéu, C. (2001). Synergistic cooperation between hypoxia and
transforming growth factor-β pathways on human vascular endothelial
growth factor gene expression. J. Biol. Chem. 276, 38527–38535.
doi: 10.1074/jbc.M104536200
Sansone, P., Savini, C., Kurelac, I., Chang, Q., Amato, L. B., Strillacci, A.,
et al. (2017). Packaging and transfer of mitochondrial DNA via exosomes
regulate escape from dormancy in hormonal therapy-resistant breast cancer.
Proc. Natl. Acad. Sci. U.S.A. 114, E9066–E9075. doi: 10.1073/pnas.170486
2114
Sarper, M., Cortes, E., Lieberthal, T. J., and Del Río Hernández, A. (2016). ATRA
modulates mechanical activation of TGF-β by pancreatic stellate cells. Sci. Rep.
6:27639. doi: 10.1038/srep27639
Frontiers in Cell and Developmental Biology | www.frontiersin.org 17 January 2021 | Volume 8 | Article 621070
Linares et al. CAFs Secretome Determinants and Functions
Savardashtaki, A., Shabaninejad, Z., Movahedpour, A., Sahebnasagh, R.,
Mirzaei, H., and Hamblin, M. R. (2019). MiRNAs derived from cancer-
associated fibroblasts in colorectal cancer. Epigenomics 11, 1627–1645.
doi: 10.2217/epi-2019-0110
Scharl, M., Frei, S., Pesch, T., Kellermeier, S., Arikkat, J., Frei, P., et al. (2013).
Interleukin-13 and transforming growth factor β synergise in the pathogenesis
of human intestinal fistulae. Gut 62, 63–72. doi: 10.1136/gutjnl-2011-300498
Scherz-Shouval, R., Santagata, S., Mendillo, M. L., Sholl, L. M., Ben-Aharon, I.,
Beck, A. H., et al. (2014). The reprogramming of tumor stroma by HSF1 is a
potent enabler of malignancy. Cell 158, 564–578. doi: 10.1016/j.cell.2014.05.045
Sewell-Loftin, M. K., Bayer, S. V. H., Crist, E., Hughes, T., Joison, S. M., Longmore,
G. D., et al. (2017). Cancer-associated fibroblasts support vascular growth
through mechanical force. Sci. Rep. 7:12574. doi: 10.1038/s41598-017-13006-x
Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac,
H., et al. (2014). Vitamin D receptor-mediated stromal reprogramming
suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159,
80–93. doi: 10.1016/j.cell.2014.08.007
Singh, M., Jha, R., Melamed, J., Shapiro, E., Hayward, S. W., and Lee, P. (2014).
Stromal androgen receptor in prostate development and cancer. Am. J. Pathol.
184, 2598–2607. doi: 10.1016/j.ajpath.2014.06.022
Sjöberg, E., Augsten, M., Bergh, J., Jirström, K., and Östman, A. (2016).
Expression of the chemokine CXCL14 in the tumour stroma is an
independent marker of survival in breast cancer. Br. J. Cancer 114, 1117–1124.
doi: 10.1038/bjc.2016.104
Song, L., Smith, M. A., Doshi, P., Sasser, K., Fulp, W., Altiok, S., et al.
(2014). Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab
in mouse xenograft models of lung cancer. J. Thorac. Oncol. 9, 974–982.
doi: 10.1097/JTO.0000000000000193
Sousa, C. M., Biancur, D. E., Wang, X., Halbrook, C. J., Sherman, M. H., Zhang,
L., et al. (2016). Pancreatic stellate cells support tumour metabolism through
autophagic alanine secretion. Nature 536, 479–483. doi: 10.1038/nature19084
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., et al.
(2012). Tumour micro-environment elicits innate resistance to RAF inhibitors
through HGF secretion. Nature 487, 500–504. doi: 10.1038/nature11183
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., et al. (2018).
CD10+GPR77+ cancer-associated fibroblasts promote cancer formation
and chemoresistance by sustaining cancer stemness. Cell 172, 841–856.e16.
doi: 10.1016/j.cell.2018.01.009
Sun, L. P., Xu, K., Cui, J., Yuan, D. Y., Zou, B., Li, J., et al. (2019). Cancer-
associated fibroblast-derived exosomal miR-382-5p promotes the migration
and invasion of oral squamous cell carcinoma. Oncol. Rep. 42, 1319–1328.
doi: 10.3892/or.2019.7255
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., et al.
(2012). Treatment-induced damage to the tumor microenvironment promotes
prostate cancer therapy resistance throughWNT16B.Nat. Med. 18, 1359–1368.
doi: 10.1038/nm.2890
Tan, W., Zhang, W., Strasner, A., Grivennikov, S., Cheng, J. Q., Hoffman, R.
M., et al. (2011). Tumour-infiltrating regulatory T cells stimulate mammary
cancermetastasis through RANKL-RANK signalling. Nature 470, 548–553.
doi: 10.1038/nature09707
Tang, D., Gao, J., Wang, S., Ye, N., Chong, Y., Huang, Y., et al. (2016). Cancer-
associated fibroblasts promote angiogenesis in gastric cancer through galectin-1
expression. Tumor Biol. 37, 1889–1899. doi: 10.1007/s13277-015-3942-9
Tanner, M. J., Welliver, R. C., Chen, M., Shtutman, M., Godoy, A., Smith, G.,
et al. (2011). Effects of androgen receptor and androgen on gene expression
in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells.
PLoS ONE 6:e0016027. doi: 10.1371/journal.pone.0016027
Tao, L., Huang, G., Wang, R., Pan, Y., He, Z., Chu, X., et al. (2016). Cancer-
associated fibroblasts treated with cisplatin facilitates chemoresistance of lung
adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway. Sci. Rep.
6:38408. doi: 10.1038/srep38408
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-
Llergo, A., Badia-Ramentol, J., Iglesias, M., et al. (2018).
TGFβ drives immune evasion in genetically reconstituted colon
cancer metastasis. Nature 554, 538–543. doi: 10.1038/nature2
5492
Tempero, M. A., van Cutsem, E., Sigal, D., Oh, D.-Y., Fazio, N., Macarulla,
T., et al. (2020). HALO 109-301: a randomized, double-blind, placebo-
controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-
paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated
hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinom. J. Clin.
Oncol. 38:638. doi: 10.1200/JCO.2020.38.4_suppl.638
Thomas, D., and Radhakrishnan, P. (2020). Role of tumor and
stroma-derived IGF/IGFBPS in pancreatic cancer. Cancers 12:1228.
doi: 10.3390/cancers12051228
Tommelein, J., de Vlieghere, E., Verset, L., Melsens, E., Leenders, J., Descamps,
B., et al. (2018). Radiotherapy-activated cancer-associated fibroblasts promote
tumor progression through paracrine IGF1R activation. Cancer Res. 78,
659–670. doi: 10.1158/0008-5472.CAN-17-0524
Toste, P. A., Nguyen, A. H., Kadera, B. E., Duong, M., Wu, N., Gawlas,
I., et al. (2016). Chemotherapy-induced inflammatory gene signature and
protumorigenic phenotype in pancreatic CAFs via stress-Associated MAPK.
Mol. Cancer Res. 14, 437–447. doi: 10.1158/1541-7786.MCR-15-0348
Tsuyada, A., Chow, A., Wu, J., Somlo, G., Chu, P., Loera, S., et al. (2012).
CCL2 mediates cross-talk between cancer cells and stromal fibroblasts
that regulates breast cancer stem cells. Cancer Res. 72, 2768–2779.
doi: 10.1158/0008-5472.CAN-11-3567
Umakoshi, M., Takahashi, S., Itoh, G., Kuriyama, S., Sasaki, Y., Yanagihara, K.,
et al. (2019). Macrophage-mediated transfer of cancer-derived components to
stromal cells contributes to establishment of a pro-tumor microenvironment.
Oncogene 38, 2162–2176. doi: 10.1038/s41388-018-0564-x
Unger, C., Kramer, N., Unterleuthner, D., Scherzer, M., Burian, A., Rudisch, A.,
et al. (2017). Stromal-derived IGF2 promotes colon cancer progression
via paracrine and autocrine mechanisms. Oncogene 36, 5341–5355.
doi: 10.1038/onc.2017.116
Unterleuthner, D., Neuhold, P., Schwarz, K., Janker, L., Neuditschko, B.,
Nivarthi, H., et al. (2020). Cancer-associated fibroblast-derived WNT2
increases tumor angiogenesis in colon cancer. Angiogenesis 23, 159–177.
doi: 10.1007/s10456-019-09688-8
Vainer, N., Dehlendorff, C., and Johansen, J. S. (2018). Systematic literature
review of IL-6 as a biomarker or treatment target in patients with
gastric, bile duct, pancreatic and colorectal cancer. Oncotarget 9:29820.
doi: 10.18632/oncotarget.25661
van Niel, G., D’Angelo, G., and Raposo, G. (2018). Shedding light on the
cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228.
doi: 10.1038/nrm.2017.125
Vangangelt, K. M. H., Tollenaar, L. S. A., van Pelt, G. W., de Kruijf, E. M., Dekker,
T. J. A., Kuppen, P. J. K., et al. (2018). The prognostic value of tumor–stroma
ratio in tumor-positive axillary lymph nodes of breast cancer patients. Int. J.
Cancer 143, 3194–3200. doi: 10.1002/ijc.31658
Vaquero, J., Lobe, C., Tahraoui, S., Claperon, A., Mergey, M., Merabtene, F.,
et al. (2018). The IgF2/IR/IGF1R pathway in tumor cells and myofibroblasts
mediates resistance to EGFR inhibition in cholangiocarcinoma. Clin. Cancer
Res. 24, 4282–4296. doi: 10.1158/1078-0432.CCR-17-3725
Vermeulen, L., de Sousa E Melo, F., van Der Heijden, M., Cameron, K., de
Jong, J. H., Borovski, T., et al. (2010). Wnt activity defines colon cancer stem
cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468–476.
doi: 10.1038/ncb2048
Vivacqua, A., Muoio, M. G., Miglietta, A. M., and Maggiolini, M. (2019).
Differential microRNA landscape triggered by estrogens in cancer associated
fibroblasts (CAFs) of primary and metastatic breast tumors. Cancers 11:412.
doi: 10.3390/cancers11030412
Wang, J.-W., Wu, X.-F., Gu, X.-J., and Jiang, X.-H. (2019). Exosomal miR-
1228 from cancer-associated fibroblasts promotes cell migration and invasion
of osteosarcoma by directly targeting SCAI. Oncol. Res. 27, 979–986.
doi: 10.3727/096504018X15336368805108
Wang, X., Zhang, L., Li, H., Sun, W., Zhang, H., and Lai, M. (2016). THBS2
is a potential prognostic biomarker in colorectal cancer. Sci. Rep. 6:33366.
doi: 10.1038/srep33366
Wang, Z., Tang, Y., Tan, Y., Wei, Q., and Yu, W. (2019). Cancer-associated
fibroblasts in radiotherapy: challenges and new opportunities. Cell Commun.
Signal. 17:47. doi: 10.1186/s12964-019-0362-2
Frontiers in Cell and Developmental Biology | www.frontiersin.org 18 January 2021 | Volume 8 | Article 621070
Linares et al. CAFs Secretome Determinants and Functions
Wang, Z., Xiong, S., Mao, Y., Chen, M., Ma, X., Zhou, X., et al. (2016). Periostin
promotes immunosuppressive premetastatic niche formation to facilitate
breast tumour metastasis. J. Pathol. 239, 484–495. doi: 10.1002/path.4747
Webber, J. P., Spary, L. K., Sanders, A. J., Chowdhury, R., Jiang, W. G., Steadman,
R., et al. (2015). Differentiation of tumour-promoting stromal myofibroblasts
by cancer exosomes. Oncogene 34, 319–333. doi: 10.1038/onc.2013.560
Wei, L., Ye, H., Li, G., Lu, Y., Zhou, Q., Zheng, S., et al. (2018). Cancer-
associated fibroblasts promote progression and gemcitabine resistance via
the SDF-1/SATB-1 pathway in pancreatic cancer. Cell Death Dis. 9:1065.
doi: 10.1038/s41419-018-1104-x
Westrich, J. A., Vermeer, D.W., Colbert, P. L., Spanos,W. C., and Pyeon, D. (2020).
The multifarious roles of the chemokine CXCL14 in cancer progression and
immune responses.Mol. Carcinog. 59, 794–806. doi: 10.1002/mc.23188
Willumsen, N., Ali, S. M., Leitzel, K., Drabick, J. J., Yee, N., Polimera, H. V., et al.
(2019). Collagen fragments quantified in serum as measures of desmoplasia
associate with survival outcome in patients with advanced pancreatic cancer.
Sci. Rep. 9:19761. doi: 10.1038/s41598-019-56268-3
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., et al. (2012).
Widespread potential for growth-factor-driven resistance to anticancer kinase
inhibitors. Nature 487, 505–509. doi: 10.1038/nature11249
Wu, S., Zhang, Y., Xu, L., Dai, Y., Teng, Y., Ma, S., et al. (2012).
Multicenter, randomized study of genetically modified recombinant human
interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer
patients receiving chemotherapy. Support. Care Cancer 20, 1875–1884.
doi: 10.1007/s00520-011-1290-x
Wu, X., Tao, P., Zhou, Q., Li, J., Yu, Z., Wang, X., et al. (2017). IL-6 secreted by
cancer-associated fibroblasts promotes epithelial-mesenchymal transition and
metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget 8,
20741–20750. doi: 10.18632/oncotarget.15119
Xiao, Q., Zhou, D., Rucki, A. A.,Williams, J., Zhou, J., Mo, G., et al. (2016). Cancer-
associated fibroblasts in pancreatic cancer are reprogrammed by tumor-
induced alterations in genomic DNA methylation. Cancer Res. 76, 5395–5404.
doi: 10.1158/0008-5472.CAN-15-3264
Xu, Y., Zhang, Z., Zhang, L., and Zhang, C. (2020). Novel module and
hub genes of distinctive breast cancer associated fibroblasts identified by
weighted gene co-expression network analysis. Breast Cancer 27, 1017–1028.
doi: 10.1007/s12282-020-01101-3
Yamaguchi, H., and Sakai, R. (2015). Direct interaction between carcinoma cells
and cancer associated fibroblasts for the regulation of cancer invasion. Cancers
7, 2054–2062. doi: 10.3390/cancers7040876
Yamanaka, T., Harimoto, N., Yokobori, T., Muranushi, R., Hoshino,
K., Hagiwara, K., et al. (2020). Nintedanib inhibits intrahepatic
cholangiocarcinoma aggressiveness via suppression of cytokines extracted
from activated cancer-associated fibroblasts. Br. J. Cancer 122, 986–994.
doi: 10.1038/s41416-020-0744-7
Yang, J., Lu, Y., Lin, Y. Y., Zheng, Z. Y., Fang, J. H., He, S., et al. (2016). Vascular
mimicry formation is promoted by paracrine TGF-β and SDF1 of cancer-
associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma.
Cancer Lett. 383, 18–27. doi: 10.1016/j.canlet.2016.09.012
Yang, L., Achreja, A., Yeung, T. L., Mangala, L. S., Jiang, D., Han, C., et al.
(2016). Targeting stromal glutamine synthetase in tumors disrupts tumor
microenvironment-regulated cancer cell growth. Cell Metab. 24, 685–700.
doi: 10.1016/j.cmet.2016.10.011
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., et al.
(2008). Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-
1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13, 23–35.
doi: 10.1016/j.ccr.2007.12.004
Yang, T., Deng, Z., Pan, Z., Qian, Y., Yao,W., andWang, J. (2020). Prognostic value
of periostin in multiple solid cancers: a systematic review with meta-analysis. J.
Cell. Physiol. 235, 2800–2808. doi: 10.1002/jcp.29184
Yang, X., Li, Y., Zou, L., and Zhu, Z. (2019). Role of exosomes in crosstalk
between cancer-associated fibroblasts and cancer cells. Front. Oncol. 9:356.
doi: 10.3389/fonc.2019.00356
Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., et al. (2016). FAP
Promotes immunosuppression by cancer-associated fibroblasts in the tumor
microenvironment via STAT3-CCL2 Signaling. Cancer Res. 76, 4124–4135.
doi: 10.1158/0008-5472.CAN-15-2973
Yano, S., Wang, W., Li, Q., Matsumoto, K., Sakurama, H., Nakamura, T.,
et al. (2008). Hepatocyte growth factor induces gefitinib resistance of lung
adenocarcinoma with epidermal growth factor receptor-activating mutations.
Cancer Res. 68, 9479–9487. doi: 10.1158/0008-5472.CAN-08-1643
Yu, B., Wu, K., Wang, X., Zhang, J., Wang, L., Jiang, Y., et al. (2018). Periostin
secreted by cancer-associated fibroblasts promotes cancer stemness in head and
neck cancer by activating protein tyrosine kinase 7. Cell Death Dis. 9:1082.
doi: 10.1038/s41419-018-1116-6
Yu, S., Xia, S., Yang, D., Wang, K., Yeh, S., Gao, Z., et al. (2013).
Androgen receptor in human prostate cancer-associated fibroblasts promotes
prostate cancer epithelial cell growth and invasion. Med. Oncol. 30:674.
doi: 10.1007/s12032-013-0674-9
Yue, H., Wang, J., Chen, R., Hou, X., Li, J., and Lu, X. (2019). Gene signature
characteristic of elevated stromal infiltration and activation is associated with
increased risk of hematogenous and lymphatic metastasis in serous ovarian
cancer. BMC Cancer 19:1266. doi: 10.1186/s12885-019-6470-y
Yuzhalin, A. E., Urbonas, T., Silva, M. A., Muschel, R. J., and Gordon-Weeks, A. N.
(2018). A core matrisome gene signature predicts cancer outcome. Br. J. Cancer
118, 435–440. doi: 10.1038/bjc.2017.458
Zhang, R., Qi, F., Zhao, F., Li, G., Shao, S., Zhang, X., et al. (2019). Cancer-
associated fibroblasts enhance tumor-associated macrophages enrichment and
suppress NK cells function in colorectal cancer. Cell Death Dis. 10:273.
doi: 10.1038/s41419-019-1435-2
Zhang, Y., Cong, X., Li, Z., and Xue, Y. (2020). Estrogen facilitates gastric
cancer cell proliferation and invasion through promoting the secretion
of interleukin-6 by cancer-associated fibroblasts. Int. Immunopharmacol.
78:105937. doi: 10.1016/j.intimp.2019.105937
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., et al. (2020).
Tumormicroenvironment-derived NRG1 promotes antiandrogen resistance in
prostate cancer. Cancer Cell 38, 279–296.e9. doi: 10.1016/j.ccell.2020.06.005
Zhao, F., Evans, K., Xiao, C., deVito, N., Theivanthiran, B., Holtzhausen, A.,
et al. (2018). Stromal fibroblasts mediate anti–PD-1 resistance via MMP-9
and dictate TGFb inhibitor sequencing in melanoma. Cancer Immunol. Res.
6, 1459–1471. doi: 10.1158/2326-6066.CIR-18-0086
Zhou, X., Yan, T., Huang, C., Xu, Z., Wang, L., Jiang, E., et al. (2018). Melanoma
cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-
associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway. J. Exp. Clin.
Cancer Res. 37:242. doi: 10.1186/s13046-018-0911-3
Zhou, Z., Zhou, Q., Wu, X., Xu, S., Hu, X., Tao, X., et al. (2020). VCAM-1
secreted from cancer-associated fibroblasts enhances the growth and invasion
of lung cancer cells through AKT andMAPK signaling.Cancer Lett. 473, 62–73.
doi: 10.1016/j.canlet.2019.12.039
Zhuang, J., Lu, Q., Shen, B., Huang, X., Shen, L., Zheng, X., et al. (2015). TGFβ1
secreted by cancer-associated fibroblasts induces epithelial-mesenchymal
transition of bladder cancer cells through lncRNA-ZEB2NAT. Sci. Rep. 5:11924.
doi: 10.1038/srep11924
Ziani, L., Safta-Saadoun, B. T., G.ourbeix, J., Cavalcanti, A., Robert, C., Favre,
G., et al. (2017). Melanoma-associated fibroblasts decrease tumor cell
susceptibility to NK cell-mediated killing through matrix-metalloproteinases
secretion. Oncotarget 8, 19780–19794. doi: 10.18632/oncotarget.
15540
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Linares, Marín-Jiménez, Badia-Ramentol and Calon. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 19 January 2021 | Volume 8 | Article 621070
